Late cytogenetic and molecular response to interferon-α (IFN-α) in chronic myelogenous leukemia (CML).

被引：0
|
作者：
Nosari, A
Perego, R
Pungolino, E
Cornacchini, G
Gargantini, L
Morra, E
机构：
[1] Niguarda Hosp, Dept Hematol, Milan, Italy
[2] Univ Milan, Inst Gen Pathol, Milan, Italy
[3] Univ Milan, CNR, Ctr Res Cellular Pathol, Milan, Italy
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2587
引用
收藏
页码：627A / 627A
页数：1
相关论文
共 50 条
  • [21] The anti-tumor activities of interferon (IFN)-α in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-α subtypes
    Yanai, Y
    Sanou, O
    Yamamoto, K
    Yamauchi, H
    Ikegami, H
    Kurimoto, M
    [J]. CANCER LETTERS, 2002, 185 (02) : 173 - 179
  • [22] Impact of interferon-αtherapy duration and chronic myelogenous leukemia (CML) history on Glivec ® (STI 571) response in interferon-resistant or intolerant CML patients in chronic and in accelerated phase.
    Michallet, M
    Le, QH
    Mates, M
    Berthaud, P
    Troncy, J
    Fiere, D
    Nicolini, F
    [J]. BLOOD, 2001, 98 (11) : 263B - 263B
  • [23] Interferon-α:: mechanisms of action in chronic myelogenous leukemia in chronic phase
    Guilhot, F
    Lacotte-Thierry, L
    [J]. HEMATOLOGY AND CELL THERAPY, 1998, 40 (05) : 237 - 239
  • [24] CYTOGENETIC HETEROGENEITY IN BLAST CRISIS (BC) OF CHRONIC MYELOGENOUS LEUKEMIA (CML)
    ABRAMSON, J
    VERMA, RS
    SCHWARTZ, J
    [J]. BLUT, 1985, 51 (05): : 361 - 363
  • [25] Sudden elastic phase (SBP) transformation in the first 2 years (yrs) of interferon-α (IFN) therapy (RX) for chronic phase (CP) chronic myelogenous leukemia (CML).
    Thomas, D
    Kantarjian, H
    O'Brien, S
    Cortes, J
    Giles, FJ
    Faderl, S
    Rios, M
    Keating, M
    Talpaz, M
    [J]. BLOOD, 1998, 92 (10) : 251A - 251A
  • [26] Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
    Kantarjian, HM
    O'Brien, S
    Cortes, JE
    Shan, JQ
    Giles, FJ
    Rios, MB
    Faderl, SH
    Wierda, WG
    Ferrajoli, A
    Verstovsek, S
    Keating, MJ
    Freireieh, EJ
    Talpaz, M
    [J]. CANCER, 2003, 97 (04) : 1033 - 1041
  • [27] Treatment of patients with multiply myeloma (MM) and chronic myelogenous leukemia (CML) with alpha-2 interferon (IFN).
    Bessmeltsev, SS
    Rukavitsyn, OA
    Abdulkadyrov, KM
    [J]. EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 711 - 711
  • [28] Pilot study of interferon alpha receptor (IFN alpha R) expression in patients with chronic myelogenous leukemia (CML).
    Spielberger, R
    Snyder, D
    Forman, SJ
    Niland, J
    Nunez, R
    Domanski, PI
    Colamonici, O
    [J]. BLOOD, 1995, 86 (10) : 2100 - 2100
  • [29] Treatment of Ph+ chronic myelogenous leukemia (CML) with interferon alfa 2B R(IFN)
    Murro, H
    Bezares, R
    Longordo, F
    Fuchs, CR
    Saidon, G
    Diaz, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : 813 - 813
  • [30] Gene transfer of alpha interferon (IFN-alpha) into hematopoietic stem cells in chronic myelogenous leukemia (CML).
    Abraham, NG
    Cook, P
    Feldman, E
    Ahmed, T
    [J]. EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 157 - 157
12345